A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients.
Ravi K. Amaravadi
No relevant relationships to disclose
Neil N. Senzer
No relevant relationships to disclose
Lainie P. Martin
No relevant relationships to disclose
Russell J. Schilder
No relevant relationships to disclose
Patricia LoRusso
No relevant relationships to disclose
Kyriakos P. Papadopoulos
No relevant relationships to disclose
David Edward Weng
Employment or Leadership Position - Tetrologic Pharmaceuticals
Stock Ownership - Tetrologic Pharmaceuticals
Martin Graham
Employment or Leadership Position - Tetrologic Pharmaceuticals
Stock Ownership - Tetrologic Pharmaceuticals
Alex A. Adjei
No relevant relationships to disclose